Reply: Was it a Sufficient Oversizing in the PARTNER 3 Trial?

Comment

Abdul Rahman Ihdayhid et al. JACC Cardiovasc Interv. 2022.

. 2022 Jan 24;15(2):228-229.

doi: 10.1016/j.jcin.2021.12.003.

No abstract available

Comment on

Impact of Annular Oversizing on Paravalvular Regurgitation and Valve Hemodynamics: New Insights From PARTNER 3.
Ihdayhid AR, Leipsic J, Hahn RT, Pibarot P, Thourani V, Makkar R, Kodali S, Russo M, Kapadia S, Chen Y, Mack M, Webb J, Bax J, Leon MB, Blanke P. Ihdayhid AR, et al. JACC Cardiovasc Interv. 2021 Oct 11;14(19):2158-2169. doi: 10.1016/j.jcin.2021.07.018. JACC Cardiovasc Interv. 2021. PMID: 34620395
Was it a Sufficient Oversizing in the PARTNER 3 Trial?
Useini D. Useini D. JACC Cardiovasc Interv. 2022 Jan 24;15(2):228. doi: 10.1016/j.jcin.2021.11.009. JACC Cardiovasc Interv. 2022. PMID: 35057995 No abstract available.